Norway: PharmaLogic finalizes purchase of majority ownership in Agilera Pharma

In recent news, PharmaLogic, a company based in the US specializing in Contract Development and Manufacturing Organization (CDMO) of radiopharmaceuticals, has acquired a majority stake in Agilera Pharma, a Norway-based CDMO, from the Institute for Energy Technology (IFE) in Norway. This strategic move by PharmaLogic signifies a significant step towards establishing the first fully-integrated global CDMO platform that focuses on radiopharmaceutical therapeutics.

PharmaLogic’s President and CEO, Etienne Montagut, expressed that the addition of Agilera’s expertise to their existing capabilities is a crucial milestone in their expansion strategy within radiopharmaceutical therapeutics. This acquisition is anticipated to bolster PharmaLogic’s proficiency in the development, manufacturing, and worldwide distribution of both commercial and clinical therapeutic radiopharmaceuticals. Furthermore, this move will broaden PharmaLogic’s geographic presence and operational capacity in the industry.

Agilera Pharma operates in three key business sectors: CDMO, where it serves as a development partner for cutting-edge radiopharmaceuticals from early-phase to clinical production stages; CMO, involving large-scale production and distribution of commercial radiopharmaceutical therapy in over 30 countries for a notable pharmaceutical company; and as a wholesaler and distributor of radiopharmaceuticals within Norway. Established in 1948 with a focus on nuclear energy research, IFE has transitioned its radiopharmaceutical activities into a flourishing CDMO with a global footprint. In 2023, IFE spun off its radiopharmaceutical business into Agilera Pharma to operate as a separate subsidiary.

Solomon Partners Securities acted as the financial advisor facilitating this acquisition, underscoring the strategic importance and financial implications of this partnership between PharmaLogic and Agilera Pharma.

This notable collaboration between PharmaLogic and Agilera Pharma is set to inspire growth and innovation within the radiopharmaceutical sector. The combined expertise and capabilities of these two entities are poised to drive advancements in the development and distribution of radiopharmaceutical therapeutics on a global scale. Through this transformative agreement, PharmaLogic is set to solidify its position as a key player in the radiopharmaceutical industry, marking a significant milestone in its pursuit of excellence and advancement in healthcare and life sciences.